Ovarian Cancer Drug Trial Began in Philadelphia
The Phase 2a study is now testing a new monotherapy for patients with platinum-resistant ovarian cancer.
Updated on Sept. 24, 2026 in Cancer
Persevere Therapeutics has treated the first patient in its Phase 2a clinical trial for misetionamide, a treatment for platinum-resistant ovarian cancer. The study is currently underway at the Abramson Cancer Center of the University of Pennsylvania.
Why it matters
Ovarian cancer affects 21,000 women in the United States annually, with 12,400 deaths, and this trial explores a new approach for patients whose cancer no longer responds to standard platinum-based chemotherapy.
This Phase 2a open-label, single-arm study is testing misetionamide in 18 patients across four U.S. academic cancer centers. Findings from this preliminary research will determine if the drug warrants further investigation for platinum-resistant ovarian cancer.
The players
Persevere Therapeutics
A pharmaceutical developer focused on identifying and testing novel oncology treatments targeting tumor growth drivers.
Abramson Cancer Center
A University of Pennsylvania research institution specializing in advanced oncological care and clinical trials.
The details
Misetionamide works by inhibiting the MYC protein, a known driver of tumor growth and cellular proliferation. By targeting this mechanism as a monotherapy, the drug aims to stop the rapid progression of malignant cells that have developed resistance to conventional platinum-based treatments.
Timeline
September 24, 2026: The first patient was treated at the Abramson Cancer Center.
September 2026: The MIROC-1 clinical trial officially initiated.
October 2026: Two additional clinical sites are expected to begin patient screening.
Health Landscape
The MIROC-1 Phase 2a study marks a specialized shift in treating platinum-resistant tumors that historically have had limited treatment options. This research moves beyond conventional chemotherapy regimens to evaluate the potential of targeted protein inhibition in oncology.
Patients dealing with platinum-resistant ovarian cancer may wish to speak with their oncologist about whether enrollment in academic clinical trials is a viable option for their care. Always discuss the eligibility requirements and potential risks of experimental treatments with your physician.
The takeaway
This trial investigates if inhibiting the MYC protein can halt the progression of treatment-resistant ovarian cancer. Patients and their care teams should track updates from academic cancer centers regarding the availability of new, targeted monotherapy trials.
Further reading
For more information on the latest research and standard treatment paths, visit Cancer.
Source note: This article includes information reported by Firstwordpharma.
